Skip to main content
SpringerLink
Log in

Antibody Therapies in Cancer

  • Chapter
  • First Online:
Book cover Progress in Cancer Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 909))

Abstract

Antibody-based immunotherapy has become a standard treatment for a variety of cancers. Many well-developed antibodies disrupt signaling of various growth factor receptors for the treatment of a number of cancers by targeting surface antigens expressed on tumor cells. In recent years, a new family of antibodies is currently emerging in the clinic, which target immune cells rather than cancer cells. These immune-targeted therapies strive to augment antitumor immune responses by antagonizing immunosuppressive pathways or providing exogenous immune-activating stimuli, which have achieved dramatic results in several cancers. The future of cancer therapies is likely to combine these approaches with other treatments, including conventional therapies, to generate more effective treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alinari, L., Lapalombella, R., Andritsos, L., Baiocchi, R. A., Lin, T. S., & Byrd, J. C. (2007). Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia. Oncogene, 26(25), 3644–3653.

    Article  CAS  PubMed  Google Scholar 

  • Allison, J. P., Hurwitz, A. A., & Leach, D. R. (1995). Manipulation of costimulatory signals to enhance antitumor T-cell responses. Current Opinion in Immunology, 7(5), 682–686.

    Article  CAS  PubMed  Google Scholar 

  • Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 26(10), 1626–1634.

    Article  CAS  PubMed  Google Scholar 

  • Amigorena, S., & Bonnerot, C. (1999). Fc receptor signaling and trafficking: A connection for antigen processing. Immunological Reviews, 172, 279–284.

    Article  CAS  PubMed  Google Scholar 

  • Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., Rodig, S. J., Chapuy, B., Ligon, A. H., Zhu, L., Grosso, J. F., Kim, S. Y., Timmerman, J. M., Shipp, M. A., & Armand, P. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England Journal of Medicine, 372(4), 311–319.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y. X., & Melero, I. (2010). Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Seminars in Oncology, 37(5), 508–516.

    Article  CAS  PubMed  Google Scholar 

  • Ascierto, P. A., Simeone, E., Sileni, V. C., Pigozzo, J., Maio, M., Altomonte, M., Del Vecchio, M., Di Guardo, L., Marchetti, P., Ridolfi, R., Cognetti, F., Testori, A., Bernengo, M. G., Guida, M., Marconcini, R., Mandala, M., Cimminiello, C., Rinaldi, G., Aglietta, M., & Queirolo, P. (2014). Clinical experience with ipilimumab 3 mg/kg: Real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 12, 116.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Awan, F. T., Lapalombella, R., Trotta, R., Butchar, J. P., Yu, B., Benson, D. M., Jr., Roda, J. M., Cheney, C., Mo, X., Lehman, A., Jones, J., Flynn, J., Jarjoura, D., Desjarlais, J. R., Tridandapani, S., Caligiuri, M. A., Muthusamy, N., & Byrd, J. C. (2010). CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood, 115(6), 1204–1213.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., & Kang, Y. K. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet, 376(9742), 687–697.

    Article  CAS  PubMed  Google Scholar 

  • Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439(7077), 682–687.

    Article  CAS  PubMed  Google Scholar 

  • Barth, M. J., Hernandez-Ilizaliturri, F. J., Mavis, C., Tsai, P. C., Gibbs, J. F., Deeb, G., & Czuczman, M. S. (2012). Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British Journal of Haematology, 156(4), 490–498.

    Article  CAS  PubMed  Google Scholar 

  • Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., Fumoleau, P., & Gianni, L. (2010). Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. Journal of Clinical Oncology, 28(7), 1138–1144.

    Article  CAS  PubMed  Google Scholar 

  • Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., Clark, E., Benyunes, M. C., Ross, G., & Swain, S. M. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine, 366(2), 109–119.

    Article  CAS  PubMed  Google Scholar 

  • Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., Torigian, D. A., O’Dwyer, P. J., & Vonderheide, R. H. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 331(6024), 1612–1616.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bensinger, W., Maziarz, R. T., Jagannath, S., Spencer, A., Durrant, S., Becker, P. S., Ewald, B., Bilic, S., Rediske, J., Baeck, J., & Stadtmauer, E. A. (2012). A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. British Journal of Haematology, 159(1), 58–66.

    Article  CAS  PubMed  Google Scholar 

  • Bonavida, B. (2007). Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 26(25), 3629–3636.

    Article  CAS  PubMed  Google Scholar 

  • Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M. S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E. K., & Ang, K. K. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 354(6), 567–578.

    Article  CAS  PubMed  Google Scholar 

  • Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Rizvi, N., Crino, L., Blumenschein, G. R., Jr., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F., & Brahmer, J. R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. The New England Journal of Medicine, 373(17), 1627–1639.

    Article  CAS  PubMed  Google Scholar 

  • Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., Gilson, M. M., Wang, C., Selby, M., Taube, J. M., Anders, R., Chen, L., Korman, A. J., Pardoll, D. M., Lowy, I., & Topalian, S. L. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28(19), 3167–3175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A., & Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine, 366(26), 2455–2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brignone, C., Escudier, B., Grygar, C., Marcu, M., & Triebel, F. (2009). A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clinical Cancer Research, 15(19), 6225–6231.

    Article  CAS  PubMed  Google Scholar 

  • Burgdorf, S., Lukacs-Kornek, V., & Kurts, C. (2006). The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. Journal of Immunology, 176(11), 6770–6776.

    Article  CAS  Google Scholar 

  • Cang, S., Mukhi, N., Wang, K., & Liu, D. (2012). Novel CD20 monoclonal antibodies for lymphoma therapy. Journal of Hematology & Oncology, 5, 64.

    Article  CAS  Google Scholar 

  • Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., & Sharma, P. (2010). Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical Cancer Research, 16(10), 2861–2871.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002). Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood, 99(3), 754–758.

    Article  CAS  PubMed  Google Scholar 

  • Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., Park, C. Y., Zhao, F., Kohrt, H. E., Malumbres, R., Briones, J., Gascoyne, R. D., Lossos, I. S., Levy, R., Weissman, I. L., & Majeti, R. (2010). Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell, 142(5), 699–713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chao, M. P., Weissman, I. L., & Majeti, R. (2012). The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Current Opinion in Immunology, 24(2), 225–232.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen, J. S., Lan, K., & Hung, M. C. (2003). Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates, 6(3), 129–136.

    Article  CAS  PubMed  Google Scholar 

  • Cheson, B. D. (2010). Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Journal of Clinical Oncology, 28(21), 3525–3530.

    Article  CAS  PubMed  Google Scholar 

  • Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., & Slamon, D. J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology, 17(9), 2639–2648.

    CAS  PubMed  Google Scholar 

  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Lederlin, P., & Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine, 346(4), 235–242.

    Article  CAS  PubMed  Google Scholar 

  • Coiffier, B., Lepretre, S., Pedersen, L. M., Gadeberg, O., Fredriksen, H., van Oers, M. H., Wooldridge, J., Kloczko, J., Holowiecki, J., Hellmann, A., Walewski, J., Flensburg, M., Petersen, J., & Robak, T. (2008). Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: A phase 1-2 study. Blood, 111(3), 1094–1100.

    Article  CAS  PubMed  Google Scholar 

  • Coppin, C., Kollmannsberger, C., Le, L., Porzsolt, F., & Wilt, T. J. (2011). Targeted therapy for advanced renal cell cancer (RCC): A cochrane systematic review of published randomised trials. BJU International, 108(10), 1556–1563.

    Article  CAS  PubMed  Google Scholar 

  • Couzin-Frankel, J. (2013). Breakthrough of the year. Cancer immunotherapy. Science, 342(6165), 1432–1433.

    Article  CAS  PubMed  Google Scholar 

  • Cragg, M. S., & Glennie, M. J. (2004). Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood, 103(7), 2738–2743.

    Article  CAS  PubMed  Google Scholar 

  • Croft, M. (2009). The role of TNF superfamily members in T-cell function and diseases. Nature Reviews Immunology, 9(4), 271–285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Czuczman, M. S., Hess, G., Gadeberg, O. V., Pedersen, L. M., Goldstein, N., Gupta, I., Jewell, R. C., Lin, T. S., Lisby, S., Strange, C., Windfeld, K., & Viardot, A. (2012). Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. British Journal of Haematology, 157(4), 438–445.

    Article  CAS  PubMed  Google Scholar 

  • Dasanu, C. A., Sethi, N., & Ahmed, N. (2012). Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opinion on Biological Therapy, 12(7), 923–937.

    Article  CAS  PubMed  Google Scholar 

  • Davies, A. J., Rohatiner, A. Z., Howell, S., Britton, K. E., Owens, S. E., Micallef, I. N., Deakin, D. P., Carrington, B. M., Lawrance, J. A., Vinnicombe, S., Mather, S. J., Clayton, J., Foley, R., Jan, H., Kroll, S., Harris, M., Amess, J., Norton, A. J., Lister, T. A., & Radford, J. A. (2004). Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 22(8), 1469–1479.

    Article  CAS  PubMed  Google Scholar 

  • Dhodapkar, K. M., Krasovsky, J., Williamson, B., & Dhodapkar, M. V. (2002). Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. The Journal of Experimental Medicine, 195(1), 125–133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Diehl, L., den Boer, A. T., Schoenberger, S. P., van der Voort, E. I., Schumacher, T. N., Melief, C. J., Offringa, R., & Toes, R. E. (1999). CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine, 5(7), 774–779.

    Article  CAS  PubMed  Google Scholar 

  • Dosio, F., Stella, B., Cerioni, S., Gastaldi, D., & Arpicco, S. (2014). Advances in anticancer antibody-drug conjugates and immunotoxins. Recent Patents on Anti-Cancer Drug Discovery, 9(1), 35–65.

    Article  CAS  PubMed  Google Scholar 

  • Ellis, L. M., & Hicklin, D. J. (2008). VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nature Reviews Cancer, 8(8), 579–591.

    Article  CAS  PubMed  Google Scholar 

  • Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., Gorbunova, V., Bay, J. O., Bodrogi, I., Jagiello-Gruszfeld, A., & Moore, N. (2007). Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet, 370(9605), 2103–2111.

    Article  PubMed  Google Scholar 

  • Fan, Q. W., Cheng, C. K., Gustafson, W. C., Charron, E., Zipper, P., Wong, R. A., Chen, J., Lau, J., Knobbe-Thomsen, C., Weller, M., Jura, N., Reifenberger, G., Shokat, K. M., & Weiss, W. A. (2013). EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell, 24(4), 438–449.

    Article  CAS  PubMed  Google Scholar 

  • Ferrajoli, A., O’Brien, S., & Keating, M. J. (2001). Alemtuzumab: A novel monoclonal antibody. Expert Opinion on Biological Therapy, 1(6), 1059–1065.

    Article  CAS  PubMed  Google Scholar 

  • Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010). Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. Journal of Clinical Oncology, 28(28), 4390–4399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F., & Coiffier, B. (2005). Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. Journal of Clinical Oncology, 23(18), 4117–4126.

    Article  CAS  PubMed  Google Scholar 

  • Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine, 207(10), 2175–2186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5(4), 317–328.

    Article  CAS  PubMed  Google Scholar 

  • French, R. R., Chan, H. T., Tutt, A. L., & Glennie, M. J. (1999). CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nature Medicine, 5(5), 548–553.

    Article  CAS  PubMed  Google Scholar 

  • Frigola, X., Inman, B. A., Lohse, C. M., Krco, C. J., Cheville, J. C., Thompson, R. H., Leibovich, B., Blute, M. L., Dong, H., & Kwon, E. D. (2011). Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clinical Cancer Research, 17(7), 1915–1923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Furman, R. R., Forero-Torres, A., Shustov, A., & Drachman, J. G. (2010). A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 51(2), 228–235.

    Article  CAS  PubMed  Google Scholar 

  • Galizia, G., Lieto, E., De Vita, F., Orditura, M., Castellano, P., Troiani, T., Imperatore, V., & Ciardiello, F. (2007). Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene, 26(25), 3654–3660.

    Article  CAS  PubMed  Google Scholar 

  • Gangadhar, T. C., & Vonderheide, R. H. (2014). Mitigating the toxic effects of anticancer immunotherapy. Nature Reviews Clinical Oncology, 11(2), 91–99.

    Article  CAS  PubMed  Google Scholar 

  • Gao, Q., Wang, X. Y., Qiu, S. J., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B. Z., Shi, Y. H., Xiao, Y. S., Xu, Y., & Fan, J. (2009). Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clinical Cancer Research, 15(3), 971–979.

    Article  CAS  PubMed  Google Scholar 

  • Gianni, L., Pienkowski, T., Im, Y. H., Roman, L., Tseng, L. M., Liu, M. C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S. A., Pedrini, J. L., Poirier, B., Morandi, P., Semiglazov, V., Srimuninnimit, V., Bianchi, G., Szado, T., Ratnayake, J., Ross, G., & Valagussa, P. (2012). Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. The Lancet Oncology, 13(1), 25–32.

    Article  CAS  PubMed  Google Scholar 

  • Grillo-Lopez, A. J., Hedrick, E., Rashford, M., & Benyunes, M. (2002). Rituximab: Ongoing and future clinical development. Seminars in Oncology, 29(1 Suppl 2), 105–112.

    Article  CAS  PubMed  Google Scholar 

  • Gupta, I. V., & Jewell, R. C. (2012). Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies. The Annals of the New York Academy of Sciences, 1263, 43–56.

    Article  PubMed  Google Scholar 

  • Hallek, M. (2013). Signaling the end of chronic lymphocytic leukemia: New frontline treatment strategies. Blood, 122(23), 3723–3734.

    Article  CAS  PubMed  Google Scholar 

  • Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., Honjo, T., & Fujii, S. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3360–3365.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gomez, H., Bastholt, L., Chasalow, S. D., & Berman, D. (2011). A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine, 9, 204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., Dronca, R., Gangadhar, T. C., Patnaik, A., Zarour, H., Joshua, A. M., Gergich, K., Elassaiss-Schaap, J., Algazi, A., Mateus, C., Boasberg, P., Tumeh, P. C., Chmielowski, B., Ebbinghaus, S. W., Li, X. N., Kang, S. P., & Ribas, A. (2013). Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England Journal of Medicine, 369(2), 134–144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Harari, P. M., Allen, G. W., & Bonner, J. A. (2007). Biology of interactions: Antiepidermal growth factor receptor agents. Journal of Clinical Oncology, 25(26), 4057–4065.

    Article  CAS  PubMed  Google Scholar 

  • Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., Ganea-Motan, E., Ciuleanu, T., Wimberger, P., Schmittel, A., Schmalfeldt, B., Burges, A., Bokemeyer, C., Lindhofer, H., Lahr, A., & Parsons, S. L. (2010). The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. International Journal of Cancer, 127(9), 2209–2221.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K. H., Neubauer, A., Dolken, G., Naumann, R., Knauf, W., Freund, M., Rohrberg, R., Hoffken, K., Franke, A., Ittel, T., Kettner, E., Haak, U., Mey, U., Klinkenstein, C., Assmann, M., & von Grunhagen, U. (2007). Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology, 25(15), 1986–1992.

    Article  CAS  PubMed  Google Scholar 

  • Hersh, E. M., O’Day, S. J., Powderly, J., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2011). A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Investigational New Drugs, 29(3), 489–498.

    Article  CAS  PubMed  Google Scholar 

  • Hilchey, S. P., Hyrien, O., Mosmann, T. R., Livingstone, A. M., Friedberg, J. W., Young, F., Fisher, R. I., Kelleher, R. J., Jr., Bankert, R. B., & Bernstein, S. H. (2009). Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a “vaccinal effect” of rituximab. Blood, 113(16), 3809–3812.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., Tamada, K., & Chen, L. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research, 65(3), 1089–1096.

    CAS  PubMed  Google Scholar 

  • Hirschi, K. K., Rohovsky, S. A., & D’Amore, P. A. (1998). PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. The Journal of Cell Biology, 141(3), 805–814.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., Padera, R., Jaklitsch, M. T., Shankar, S., Chen, T. C., Korman, A., Allison, J. P., & Dranoff, G. (2003). Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 100(8), 4712–4717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., Friedlander, P., Flaherty, K. T., Murphy, G. F., Rodig, S., Velazquez, E. F., Mihm, M. C., Jr., Russell, S., DiPiro, P. J., Yap, J. T., Ramaiya, N., Van den Abbeele, A. D., Gargano, M., & McDermott, D. (2014). Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Research, 2(7), 632–642.

    Article  CAS  Google Scholar 

  • Hudis, C. A. (2007). Trastuzumab – Mechanism of action and use in clinical practice. The New England Journal of Medicine, 357(1), 39–51.

    Article  CAS  PubMed  Google Scholar 

  • Hughes, B. (2010). Antibody-drug conjugates for cancer: Poised to deliver? Nature Reviews Drug Discovery, 9(9), 665–667.

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., Ferrara, N., Fyfe, G., Rogers, B., Ross, R., & Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine, 350(23), 2335–2342.

    Article  CAS  PubMed  Google Scholar 

  • Hussein, M., Berenson, J. R., Niesvizky, R., Munshi, N., Matous, J., Sobecks, R., Harrop, K., Drachman, J. G., & Whiting, N. (2010). A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica, 95(5), 845–848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jiang, J., Zhu, Y., Wu, C., Shen, Y., Wei, W., Chen, L., Zheng, X., Sun, J., Lu, B., & Zhang, X. (2010). Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer. Cancer Immunology, Immunotherapy, 59(11), 1707–1714.

    Article  CAS  PubMed  Google Scholar 

  • Jones, B. (2013). Haematological cancer: Rituximab maintenance improves the outcome of elderly patients with FL. Nature Reviews. Clinical Oncology, 10(11), 607.

    Article  PubMed  Google Scholar 

  • Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993). Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. The New England Journal of Medicine, 329(7), 459–465.

    Article  CAS  PubMed  Google Scholar 

  • Katz, J., Janik, J. E., & Younes, A. (2011). Brentuximab vedotin (SGN-35). Clinical Cancer Research, 17(20), 6428–6436.

    Article  CAS  PubMed  Google Scholar 

  • Kim, R. (2009). Cetuximab and panitumumab: Are they interchangeable? The Lancet Oncology, 10(12), 1140–1141.

    Article  PubMed  Google Scholar 

  • Kim, P. S., Armstrong, T. D., Song, H., Wolpoe, M. E., Weiss, V., Manning, E. A., Huang, L. Q., Murata, S., Sgouros, G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2008). Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. The Journal of Clinical Investigation, 118(5), 1700–1711.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kohler, G., & Milstein, C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256(5517), 495–497.

    Article  CAS  PubMed  Google Scholar 

  • Krambeck, A. E., Thompson, R. H., Dong, H., Lohse, C. M., Park, E. S., Kuntz, S. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2006). B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival. Proceedings of the National Academy of Sciences of the United States of America, 103(27), 10391–10396.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Le, D. T., Lutz, E., Uram, J. N., Sugar, E. A., Onners, B., Solt, S., Zheng, L., Diaz, L. A., Jr., Donehower, R. C., Jaffee, E. M., & Laheru, D. A. (2013). Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of Immunotherapy, 36(7), 382–389.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., de la Chapelle, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R. H., Wood, L. D., Cuka, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Zhou, S., Cornish, T. C., Taube, J. M., Anders, R. A., Eshleman, J. R., Vogelstein, B., & Diaz, L. A., Jr. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine, 372(26), 2509–2520.

    Article  CAS  PubMed  Google Scholar 

  • Lebbe, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O’Day, S. J., Konto, C., Cykowski, L., McHenry, M. B., & Wolchok, J. D. (2014). Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology, 25(11), 2277–2284.

    Article  CAS  PubMed  Google Scholar 

  • Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J., Kussie, P., & Ferguson, K. M. (2005). Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell, 7(4), 301–311.

    Article  CAS  PubMed  Google Scholar 

  • Li, D., Ji, H., Zaghlul, S., McNamara, K., Liang, M. C., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Scott, A. M., Jungbluth, A. A., Cavenee, W. K., Old, L. J., Demetri, G. D., & Wong, K. K. (2007). Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. The Journal of Clinical Investigation, 117(2), 346–352.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Long, E. O. (2008). Negative signaling by inhibitory receptors: The NK cell paradigm. Immunological Reviews, 224, 70–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., Son, T., Chen, Y., Easton, A. N., Li, J. C., Rillema, J. R., Licea, M., Fieger, C., Liang, T. W., Mather, J. P., Koenig, S., Stewart, S. J., Johnson, S., Bonvini, E., & Moore, P. A. (2012). Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clinical Cancer Research, 18(14), 3834–3845.

    Article  CAS  PubMed  Google Scholar 

  • LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011). Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clinical Cancer Research, 17(20), 6437–6447.

    Article  CAS  PubMed  Google Scholar 

  • Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., Zaniboni, A., Tonini, G., Buonadonna, A., Amoroso, D., Chiara, S., Carlomagno, C., Boni, C., Allegrini, G., Boni, L., & Falcone, A. (2014). Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. The New England Journal of Medicine, 371(17), 1609–1618.

    Article  PubMed  CAS  Google Scholar 

  • Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J. M., & Reck, M. (2012). Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study. Journal of Clinical Oncology, 30(17), 2046–2054.

    Article  CAS  PubMed  Google Scholar 

  • Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C., Kleiner, D., Mavroukakis, S. A., Yellin, M., & Rosenberg, S. A. (2005). Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Annals of Surgical Oncology, 12(12), 1005–1016.

    Article  PubMed  PubMed Central  Google Scholar 

  • Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., & Wasik, M. A. (2008). Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America, 105(52), 20852–20857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., Old, L. J., & Odunsi, K. (2010). Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(17), 7875–7880.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S., & Chen, L. (1997). Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Medicine, 3(6), 682–685.

    Article  CAS  PubMed  Google Scholar 

  • Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984). Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proceedings of the National Academy of Sciences of the United States of America, 81(21), 6851–6855.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mullard, A. (2013). Maturing antibody-drug conjugate pipeline hits 30. Nature Reviews Drug Discovery, 12(5), 329–332.

    Article  CAS  PubMed  Google Scholar 

  • Osenga, K. L., Hank, J. A., Albertini, M. R., Gan, J., Sternberg, A. G., Eickhoff, J., Seeger, R. C., Matthay, K. K., Reynolds, C. P., Twist, C., Krailo, M., Adamson, P. C., Reisfeld, R. A., Gillies, S. D., & Sondel, P. M. (2006). A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children’s Oncology Group. Clinical Cancer Research, 12(6), 1750–1759.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ott, M. G., Marme, F., Moldenhauer, G., Lindhofer, H., Hennig, M., Spannagl, R., Essing, M. M., Linke, R., & Seimetz, D. (2012). Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites. International Journal of Cancer, 130(9), 2195–2203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., Liu, Y., Tang, J., Wang, S., & Fu, Y. X. (2010). The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell, 18(2), 160–170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., Mischel, P. S., Stokoe, D., & Pieper, R. O. (2007). Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nature Medicine, 13(1), 84–88.

    Article  CAS  PubMed  Google Scholar 

  • Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G., Parren, P. W., & Taylor, R. P. (2009). Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): Considerably higher levels of CDC are induced by OFA than by RTX. Journal of Immunology, 183(1), 749–758.

    Article  CAS  Google Scholar 

  • Paz-Ares, L., Mezger, J., Ciuleanu, T. E., Fischer, J. R., von Pawel, J., Provencio, M., Kazarnowicz, A., Losonczy, G., de Castro, G., Jr., Szczesna, A., Crino, L., Reck, M., Ramlau, R., Ulsperger, E., Schumann, C., Miziara, J. E., Lessa, A. E., Dediu, M., Balint, B., Depenbrock, H., Soldatenkova, V., Kurek, R., Hirsch, F. R., Thatcher, N., & Socinski, M. A. (2015). Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): An open-label, randomised, controlled phase 3 study. The Lancet Oncology, 16(3), 328–337.

    Article  CAS  PubMed  Google Scholar 

  • Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009). Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. The Journal of Experimental Medicine, 206(8), 1717–1725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peipp, M., Lammerts van Bueren, J. J., Schneider-Merck, T., Bleeker, W. W., Dechant, M., Beyer, T., Repp, R., van Berkel, P. H., Vink, T., van de Winkel, J. G., Parren, P. W., & Valerius, T. (2008). Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood, 112(6), 2390–2399.

    Article  CAS  PubMed  Google Scholar 

  • Pickup, M., Novitskiy, S., & Moses, H. L. (2013). The roles of TGFbeta in the tumour microenvironment. Nature Reviews Cancer, 13(11), 788–799.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England Journal of Medicine, 365(8), 725–733.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Postow, M. A., Callahan, M. K., Barker, C. A., Yamada, Y., Yuan, J., Kitano, S., Mu, Z., Rasalan, T., Adamow, M., Ritter, E., Sedrak, C., Jungbluth, A. A., Chua, R., Yang, A. S., Roman, R. A., Rosner, S., Benson, B., Allison, J. P., Lesokhin, A. M., Gnjatic, S., & Wolchok, J. D. (2012). Immunologic correlates of the abscopal effect in a patient with melanoma. The New England Journal of Medicine, 366(10), 925–931.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012). CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research, 18(7), 2039–2047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pro, B., Advani, R., Brice, P., Bartlett, N. L., Rosenblatt, J. D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J. M., Yang, Y., Sievers, E. L., Kennedy, D. A., & Shustov, A. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. Journal of Clinical Oncology, 30(18), 2190–2196.

    Article  CAS  PubMed  Google Scholar 

  • Racila, E., Link, B. K., Weng, W. K., Witzig, T. E., Ansell, S., Maurer, M. J., Huang, J., Dahle, C., Halwani, A., Levy, R., & Weiner, G. J. (2008). A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clinical Cancer Research, 14(20), 6697–6703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Recher, C., Coiffier, B., Haioun, C., Molina, T. J., Ferme, C., Casasnovas, O., Thieblemont, C., Bosly, A., Laurent, G., Morschhauser, F., Ghesquieres, H., Jardin, F., Bologna, S., Fruchart, C., Corront, B., Gabarre, J., Bonnet, C., Janvier, M., Canioni, D., Jais, J. P., Salles, G., & Tilly, H. (2011). Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial. Lancet, 378(9806), 1858–1867.

    Article  CAS  PubMed  Google Scholar 

  • Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J. M., & Lynch, T. J. (2013). Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology, 24(1), 75–83.

    Article  CAS  PubMed  Google Scholar 

  • Ribas, A., Kefford, R., Marshall, M. A., Punt, C. J., Haanen, J. B., Marmol, M., Garbe, C., Gogas, H., Schachter, J., Linette, G., Lorigan, P., Kendra, K. L., Maio, M., Trefzer, U., Smylie, M., McArthur, G. A., Dreno, B., Nathan, P. D., Mackiewicz, J., Kirkwood, J. M., Gomez-Navarro, J., Huang, B., Pavlov, D., & Hauschild, A. (2013). Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. Journal of Clinical Oncology, 31(5), 616–622.

    Article  CAS  PubMed  Google Scholar 

  • Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S. S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., & Small, E. J. (2008). Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. Journal of Clinical Oncology, 26(33), 5422–5428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E. B., Merghoub, T., Wolchok, J. D., Schumacher, T. N., & Chan, T. A. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124–128.

    Article  CAS  PubMed  Google Scholar 

  • Robert, N., Leyland-Jones, B., Asmar, L., Belt, R., Ilegbodu, D., Loesch, D., Raju, R., Valentine, E., Sayre, R., Cobleigh, M., Albain, K., McCullough, C., Fuchs, L., & Slamon, D. (2006). Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 24(18), 2786–2792.

    Article  CAS  PubMed  Google Scholar 

  • Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J. F., Testori, A., Grob, J. J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Jr., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T. T., Humphrey, R., Hoos, A., & Wolchok, J. D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364(26), 2517–2526.

    Article  CAS  PubMed  Google Scholar 

  • Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W. J., Gangadhar, T. C., Patnaik, A., Dronca, R., Zarour, H., Joseph, R. W., Boasberg, P., Chmielowski, B., Mateus, C., Postow, M. A., Gergich, K., Elassaiss-Schaap, J., Li, X. N., Iannone, R., Ebbinghaus, S. W., Kang, S. P., & Daud, A. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet, 384(9948), 1109–1117.

    Article  CAS  PubMed  Google Scholar 

  • Roopenian, D. C., & Akilesh, S. (2007). FcRn: The neonatal Fc receptor comes of age. Nature Reviews Immunology, 7(9), 715–725.

    Article  CAS  PubMed  Google Scholar 

  • Ruter, J., Antonia, S. J., Burris, H. A., Huhn, R. D., & Vonderheide, R. H. (2010). Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biology and Therapy, 10(10), 983–993.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saenger, Y. M., & Wolchok, J. D. (2008). The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immunity, 8, 1.

    PubMed  PubMed Central  Google Scholar 

  • Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine, 207(10), 2187–2194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T. S., Rivera, F., Couture, F., Sirzen, F., & Cassidy, J. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. Journal of Clinical Oncology, 26(12), 2013–2019.

    Article  CAS  PubMed  Google Scholar 

  • Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Journal of Medicine, 355(24), 2542–2550.

    Article  CAS  PubMed  Google Scholar 

  • Scalapino, K. J., & Daikh, D. I. (2008). CTLA-4: A key regulatory point in the control of autoimmune disease. Immunological Reviews, 223, 143–155.

    Article  CAS  PubMed  Google Scholar 

  • Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T. T., Berman, D. M., & Wolchok, J. D. (2015). Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology, 33(17), 1889–1894.

    Article  CAS  PubMed  Google Scholar 

  • Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., Grantcharova, V., Kohli, N., West, K. A., Leszczyniecka, M., Feldhaus, M. J., Kudla, A. J., & Nielsen, U. B. (2009). Therapeutically targeting ErbB3: A key node in ligand-induced activation of the ErbB receptor-PI3K axis. Science Signaling, 2(77), ra31.

    Article  PubMed  CAS  Google Scholar 

  • Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74.

    Article  CAS  PubMed  Google Scholar 

  • Scott, S. D. (1998). Rituximab: A new therapeutic monoclonal antibody for non-Hodgkin’s lymphoma. Cancer Practice, 6(3), 195–197.

    Article  CAS  PubMed  Google Scholar 

  • Scott, A. M., Lee, F. T., Tebbutt, N., Herbertson, R., Gill, S. S., Liu, Z., Skrinos, E., Murone, C., Saunder, T. H., Chappell, B., Papenfuss, A. T., Poon, A. M., Hopkins, W., Smyth, F. E., MacGregor, D., Cher, L. M., Jungbluth, A. A., Ritter, G., Brechbiel, M. W., Murphy, R., Burgess, A. W., Hoffman, E. W., Johns, T. G., & Old, L. J. (2007). A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America, 104(10), 4071–4076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., Murphy, M., Stewart, S. J., & Keefe, D. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20(5), 1215–1221.

    Article  CAS  PubMed  Google Scholar 

  • Shen, J., Vil, M. D., Prewett, M., Damoci, C., Zhang, H., Li, H., Jimenez, X., Deevi, D. S., Iacolina, M., Kayas, A., Bassi, R., Persaud, K., Rohoza-Asandi, A., Balderes, P., Loizos, N., Ludwig, D. L., Tonra, J., Witte, L., & Zhu, Z. (2009). Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia, 11(6), 594–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., Pearson, T. C., Ledbetter, J. A., Aruffo, A., & Mittler, R. S. (1997). 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. The Journal of Experimental Medicine, 186(1), 47–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012). Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology, 22(1), 3–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., Gan, J., Eickhoff, J., DeSantes, K. B., Cohn, S. L., Hecht, T., Gadbaw, B., Reisfeld, R. A., Maris, J. M., & Sondel, P. M. (2010). Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) phase II study. Journal of Clinical Oncology, 28(33), 4969–4975.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sia, D., Alsinet, C., Newell, P., & Villanueva, A. (2014). VEGF signaling in cancer treatment. Current Pharmaceutical Design, 20(17), 2834–2842.

    Article  CAS  PubMed  Google Scholar 

  • Sievers, E. L., & Senter, P. D. (2013). Antibody-drug conjugates in cancer therapy. Annual Review of Medicine, 64, 15–29.

    Article  CAS  PubMed  Google Scholar 

  • Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. The New England Journal of Medicine, 344(11), 783–792.

    Article  CAS  PubMed  Google Scholar 

  • Slovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., & Beer, T. M. (2013). Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I/II study. Annals of Oncology, 24(7), 1813–1821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., Hollmann, T. J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C. T., Wang, L., Ribas, A., Wolchok, J. D., & Chan, T. A. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine, 371(23), 2189–2199.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013). Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Science Translational Medicine, 5(200), 200ra116.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Spratlin, J. (2011). Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Current Oncology Reports, 13(2), 97–102.

    Article  CAS  PubMed  Google Scholar 

  • Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011). Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences of the United States of America, 108(17), 7142–7147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., McPherson, A., Meissner, B., Okoye, U. C., Diepstra, A., van den Berg, A., Sun, M., Leung, G., Jones, S. J., Connors, J. M., Huntsman, D. G., Savage, K. J., Rimsza, L. M., Horsman, D. E., Staudt, L. M., Steidl, U., Marra, M. A., & Gascoyne, R. D. (2011). MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 471(7338), 377–381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sullivan, L. A., & Brekken, R. A. (2010). The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs, 2(2), 165–175.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tamura, K., Shimizu, C., Hojo, T., Akashi-Tanaka, S., Kinoshita, T., Yonemori, K., Kouno, T., Katsumata, N., Ando, M., Aogi, K., Koizumi, F., Nishio, K., & Fujiwara, Y. (2011). FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Annals of Oncology, 22(6), 1302–1307.

    Article  CAS  PubMed  Google Scholar 

  • Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014). Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical Cancer Research, 20(19), 5064–5074.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Taylor, C., Hershman, D., Shah, N., Suciu-Foca, N., Petrylak, D. P., Taub, R., Vahdat, L., Cheng, B., Pegram, M., Knutson, K. L., & Clynes, R. (2007). Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clinical Cancer Research, 13(17), 5133–5143.

    Article  CAS  PubMed  Google Scholar 

  • Teeling, J. L., French, R. R., Cragg, M. S., van den Brakel, J., Pluyter, M., Huang, H., Chan, C., Parren, P. W., Hack, C. E., Dechant, M., Valerius, T., van de Winkel, J. G., & Glennie, M. J. (2004). Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 104(6), 1793–1800.

    Article  CAS  PubMed  Google Scholar 

  • Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., Blute, M. L., Sebo, T. J., Cheville, J. C., & Kwon, E. D. (2006). Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Research, 66(7), 3381–3385.

    Article  CAS  PubMed  Google Scholar 

  • Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007). PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clinical Cancer Research, 13(6), 1757–1761.

    Article  CAS  PubMed  Google Scholar 

  • Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., & Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine, 366(26), 2443–2454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., Leming, P. D., Lipson, E. J., Puzanov, I., Smith, D. C., Taube, J. M., Wigginton, J. M., Kollia, G. D., Gupta, A., Pardoll, D. M., Sosman, J. A., & Hodi, F. S. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32(10), 1020–1030.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Topp, M. S., Kufer, P., Gokbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H. A., Raff, T., Viardot, A., Schmid, M., Stelljes, M., Schaich, M., Degenhard, E., Kohne-Volland, R., Bruggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baeuerle, P. A., Kneba, M., Einsele, H., Riethmuller, G., Hoelzer, D., Zugmaier, G., & Bargou, R. C. (2011). Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Journal of Clinical Oncology, 29(18), 2493–2498.

    Article  CAS  PubMed  Google Scholar 

  • Topp, M. S., Gokbuget, N., Stein, A. S., Zugmaier, G., O’Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., Neumann, S., Foa, R., Litzow, M., Ribera, J. M., Rambaldi, A., Schiller, G., Bruggemann, M., Horst, H. A., Holland, C., Jia, C., Maniar, T., Huber, B., Nagorsen, D., Forman, S. J., & Kantarjian, H. M. (2015). Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study. The Lancet Oncology, 16(1), 57–66.

    Article  CAS  PubMed  Google Scholar 

  • Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., & Ribas, A. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515(7528), 568–571.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vaickus, L., & Foon, K. A. (1991). Overview of monoclonal antibodies in the diagnosis and therapy of cancer. Cancer Investigation, 9(2), 195–209.

    Article  CAS  PubMed  Google Scholar 

  • Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J. L., Van Laethem, J. L., Maurel, J., Richardson, G., Wolf, M., & Amado, R. G. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. Journal of Clinical Oncology, 25(13), 1658–1664.

    Article  PubMed  CAS  Google Scholar 

  • Van Cutsem, E., Kohne, C. H., Hitre, E., Zaluski, J., Chang Chien, C. R., Makhson, A., D’Haens, G., Pinter, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine, 360(14), 1408–1417.

    Article  PubMed  Google Scholar 

  • Van Cutsem, E., Kohne, C. H., Lang, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., Schlichting, M., Zubel, A., Celik, I., Rougier, P., & Ciardiello, F. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology, 29(15), 2011–2019.

    Article  PubMed  CAS  Google Scholar 

  • van Meerten, T., & Hagenbeek, A. (2010). CD20-targeted therapy: The next generation of antibodies. Seminars in Hematology, 47(2), 199–210.

    Article  PubMed  CAS  Google Scholar 

  • van Zelm, M. C., van der Burg, M., de Ridder, D., Barendregt, B. H., de Haas, E. F., Reinders, M. J., Lankester, A. C., Revesz, T., Staal, F. J., & van Dongen, J. J. (2005). Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. Journal of Immunology, 175(9), 5912–5922.

    Article  Google Scholar 

  • Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D. Y., Dieras, V., Guardino, E., Fang, L., Lu, M. W., Olsen, S., & Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England Journal of Medicine, 367(19), 1783–1791.

    Article  CAS  PubMed  Google Scholar 

  • Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., Knecht, R., Amellal, N., Schueler, A., & Baselga, J. (2007). Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. Journal of Clinical Oncology, 25(16), 2171–2177.

    Article  CAS  PubMed  Google Scholar 

  • Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., Erfan, J., Zabolotnyy, D., Kienzer, H. R., Cupissol, D., Peyrade, F., Benasso, M., Vynnychenko, I., De Raucourt, D., Bokemeyer, C., Schueler, A., Amellal, N., & Hitt, R. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England Journal of Medicine, 359(11), 1116–1127.

    Article  CAS  PubMed  Google Scholar 

  • Vey, N., Bourhis, J. H., Boissel, N., Bordessoule, D., Prebet, T., Charbonnier, A., Etienne, A., Andre, P., Romagne, F., Benson, D., Dombret, H., & Olive, D. (2012). A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 120(22), 4317–4323.

    Article  CAS  PubMed  Google Scholar 

  • Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20(3), 719–726.

    Article  CAS  PubMed  Google Scholar 

  • von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., Baumann, K. H., Clemens, M. R., Duerr, R., Uleer, C., Andersson, M., Stein, R. C., Nekljudova, V., & Loibl, S. (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. Journal of Clinical Oncology, 27(12), 1999–2006.

    Article  CAS  Google Scholar 

  • Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M. S., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., Green, S. J., O’Dwyer, P. J., Running, K. L., Huhn, R. D., & Antonia, S. J. (2007). Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. Journal of Clinical Oncology, 25(7), 876–883.

    Article  CAS  PubMed  Google Scholar 

  • Walter, R. B. (2014). Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia. Expert Review of Hematology, 7(3), 317–319.

    Article  CAS  PubMed  Google Scholar 

  • Wang, S., & Chen, L. (2004). Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes and Infection, 6(8), 759–766.

    Article  CAS  PubMed  Google Scholar 

  • Wang-Gillam, A., Plambeck-Suess, S., Goedegebuure, P., Simon, P. O., Mitchem, J. B., Hornick, J. R., Sorscher, S., Picus, J., Suresh, R., Lockhart, A. C., Tan, B., & Hawkins, W. G. (2013). A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Investigational New Drugs, 31(3), 707–713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008). Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology, 26(36), 5950–5956.

    Article  CAS  PubMed  Google Scholar 

  • Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., Kroeger, J., Eysmans, C., Sarnaik, A. A., & Chen, Y. A. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Journal of Clinical Oncology, 31(34), 4311–4318.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weinberg, A. D., Rivera, M. M., Prell, R., Morris, A., Ramstad, T., Vetto, J. T., Urba, W. J., Alvord, G., Bunce, C., & Shields, J. (2000). Engagement of the OX-40 receptor in vivo enhances antitumor immunity. Journal of Immunology, 164(4), 2160–2169.

    Article  CAS  Google Scholar 

  • Weinberg, A. D., Morris, N. P., Kovacsovics-Bankowski, M., Urba, W. J., & Curti, B. D. (2011). Science gone translational: The OX40 agonist story. Immunological Reviews, 244(1), 218–231.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Weiner, L. M., Belldegrun, A. S., Crawford, J., Tolcher, A. W., Lockbaum, P., Arends, R. H., Navale, L., Amado, R. G., Schwab, G., & Figlin, R. A. (2008). Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clinical Cancer Research, 14(2), 502–508.

    Article  CAS  PubMed  Google Scholar 

  • Whiteside, T. L., Stanson, J., Shurin, M. R., & Ferrone, S. (2004). Antigen-processing machinery in human dendritic cells: Up-regulation by maturation and down-regulation by tumor cells. Journal of Immunology, 173(3), 1526–1534.

    Article  CAS  Google Scholar 

  • Wierda, W. G., Padmanabhan, S., Chan, G. W., Gupta, I. V., Lisby, S., & Osterborg, A. (2011). Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the phase 2 international study. Blood, 118(19), 5126–5129.

    Article  CAS  PubMed  Google Scholar 

  • Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., & White, C. A. (2002). Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 20(10), 2453–2463.

    Article  CAS  PubMed  Google Scholar 

  • Wolchok, J. D., Hoos, A., O’Day, S., Weber, J. S., Hamid, O., Lebbe, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., Humphrey, R., & Hodi, F. S. (2009). Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clinical Cancer Research, 15(23), 7412–7420.

    Article  CAS  PubMed  Google Scholar 

  • Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R. A., Reed, K., Burke, M. M., Caldwell, A., Kronenberg, S. A., Agunwamba, B. U., Zhang, X., Lowy, I., Inzunza, H. D., Feely, W., Horak, C. E., Hong, Q., Korman, A. J., Wigginton, J. M., Gupta, A., & Sznol, M. (2013). Nivolumab plus ipilimumab in advanced melanoma. The New England Journal of Medicine, 369(2), 122–133.

    Article  CAS  PubMed  Google Scholar 

  • Wu, Y., Zhong, Z., Huber, J., Bassi, R., Finnerty, B., Corcoran, E., Li, H., Navarro, E., Balderes, P., Jimenez, X., Koo, H., Mangalampalli, V. R., Ludwig, D. L., Tonra, J. R., & Hicklin, D. J. (2006). Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer. Clinical Cancer Research, 12(21), 6573–6584.

    Article  CAS  PubMed  Google Scholar 

  • Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., Lowy, I., White, D. E., & Rosenberg, S. A. (2007). Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy, 30(8), 825–830.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137.

    Article  CAS  PubMed  Google Scholar 

  • Yeung, Y. A., Leabman, M. K., Marvin, J. S., Qiu, J., Adams, C. W., Lien, S., Starovasnik, M. A., & Lowman, H. B. (2009). Engineering human IgG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates. Journal of Immunology, 182(12), 7663–7671.

    Article  CAS  Google Scholar 

  • Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010). Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England Journal of Medicine, 363(19), 1812–1821.

    Article  CAS  PubMed  Google Scholar 

  • Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., Forero-Torres, A., Moskowitz, C. H., Connors, J. M., Engert, A., Larsen, E. K., Kennedy, D. A., Sievers, E. L., & Chen, R. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. Journal of Clinical Oncology, 30(18), 2183–2189.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yu, B., Mao, Y., Bai, L. Y., Herman, S. E., Wang, X., Ramanunni, A., Jin, Y., Mo, X., Cheney, C., Chan, K. K., Jarjoura, D., Marcucci, G., Lee, R. J., Byrd, J. C., Lee, L. J., & Muthusamy, N. (2013). Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood, 121(1), 136–147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P. (2007). B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proceedings of the National Academy of Sciences of the United States of America, 104(49), 19458–19463.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H. M., Borucka, E., Lurje, G., Sherrod, A. E., Iqbal, S., Groshen, S., & Lenz, H. J. (2007). FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of Clinical Oncology, 25(24), 3712–3718.

    Article  CAS  PubMed  Google Scholar 

  • Zou, W., & Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 8(6), 467–477.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Datun Road #15, Chaoyang District, 100101, Beijing, China

    Shengdian Wang & Mingming Jia

Authors
  1. Shengdian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mingming Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shengdian Wang .

Editor information

Editors and Affiliations

  1. Dept. of Immunology, Cancer Inst & Hospi, Chinese Acad Med & Peking Med Coll, Beijing, China

    Shuren Zhang

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Wang, S., Jia, M. (2016). Antibody Therapies in Cancer. In: Zhang, S. (eds) Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, vol 909. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7555-7_1

Download citation

Publish with us

Policies and ethics

Search

Navigation